Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Nanobiotix S.A.NASDAQ: NBTX

Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Financing cash flow turns positive

Q4 FY2025 financing cash flow was €40.25M, compared with -€2.48M a year earlier.

Context

  • Financing cash flow amounted to 126.2% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
€40.25M— QoQ
Last fiscal yearDec 2025
€37.42M+828.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1722.8%——
1 year+828.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

EUR · from the cash flow

Latest · FY2025
37.42M EUR
Year-over-year change
+828.6%

Financing Cash Flow vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +828.6% is the 3rd highest of 10, against a peer median of -16.8%.
  • Financing cash flow amounts to 126.2% of revenue for NBTX, versus a peer median of 14.7%.
NBTX Competitors
Financing Cash Flow for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$376.3M USD-16.8%+19.7%206.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$251.18M USD+3158.7%+6.2%—
TYRATyra Biosciences, Inc.LTM Mar 2026$166.3M USD+4048.1%+134.0%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$151.78M USD+62.0%+41.1%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$107.35M USD—+221.5%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$45.17M USD-0.0%—19.9%
NBTXNanobiotix S.A.FY2025€37.42M EUR+828.6%—126.2%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$20.66M USD-94.1%-57.0%9.5%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$13.61M USD-39.4%+1.5%—
KURAKura Oncology, Inc.LTM Mar 2026$1.72M USD-72.2%-64.0%2.4%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$363K USD-101.7%——
Peer median (excluding NBTX) —-16.8%+12.9%14.7%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Depreciation & Amortization1.56M1.5M1.51M1.62M1.5M
Deferred Income Tax00003K
Stock-Based Compensation3.2M3.17M3.3M4.3M3.54M
Change in Working Capital(4.7M)(606K)(367K)131K(3.4M)
Accounts Receivables62K(101K)(806K)(2.07M)1.85M
Inventory00000
Accounts Payables00000
Other Working Capital(4.76M)(505K)439K2.2M(5.25M)
Other Non-Cash Items17.07M15.87M22.78M42.53M(11.1M)
Operating Cash Flow(29.87M)(37.1M)(12.48M)(19.55M)(33.42M)
Capital Expenditures(228K)(92K)(328K)(846K)(546K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(14K)230K(21K)(109K)(40K)
Investing Cash Flow(242K)138K(349K)(955K)(578K)
Debt Repayment(3.74M)(4.74M)(3.62M)(4.16M)38.19M
Common Stock Issued00001.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.44M)(916K)50.39M(980K)(2.31M)
Financing Cash Flow(5.18M)(5.65M)46.77M(5.14M)37.42M
Effect of Forex Changes64K83K(51K)94K(402K)
Net Change in Cash(35.23M)(42.53M)33.9M(25.55M)3.01M
Free Cash Flow(30.1M)(37.2M)(12.8M)(20.4M)(33.97M)

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.